INNV Stock Forecast & Price Target

InnovAge Holding is well-positioned for long-term success, as it addresses two major challenges in the healthcare industry and has the potential to further expand its reach through discussions with CMS and other stakeholders. We expect the company's FY27 guidance to exceed current expectations, driven by initiatives to enhance the member experience and invest in technology. Additionally, we believe INNV's strong financial performance and potential for margin expansion make it an attractive investment opportunity with potential for upside from its M&A strategy and efficient operations. However, potential risks associated with the transition to the v28 risk adjustment model and state budget pressures should continue to be monitored.

InnovAge Holding is a healthcare delivery platform that has seen strong financial performance with EBITDA increasing by 114% year over year and revenues surpassing consensus estimates by 10%. However, potential risks for the company include regulatory risks in the Medicare and Medicaid markets, maintaining profitability in at-risk contracts, and potential disruptions from public health emergencies. These risks could impede the stock from achieving its long-term valuation multiple, making the current valuation of 10-15x EBITDA and price target of $13 seem overpriced.